Karolinska Institutet Holding AB, a A wholly owned company of Karolinska Institute, a Swedish research institute, has signed an agreement with Johnson & Johnson Innovation. The collaboration aims to strengthen innovation at Karolinska Institute and integrate it into product and business development, as well as to form a research collaboration between the Karolinska Institutet and Janssen Pharmaceuticals.

As part of the collaboration, Johnson & Johnson Innovation will establish a life science innovation hub at Karolinska Institutet to work with Karolinska Institutet Holding AB, to support and drive the growth of life science companies rooted in academic medical research. The collaboration benefits between Karolinska Institutet Holding AB and Johnson & Johnson Innovation serves to meet the needs of entrepreneurs in the pharmaceutical, medical technology and healthcare sectors. It will include knowledge sharing, establishment of coaching and scouting programs, investments in developing ideas into finished concepts, and funding for start-ups.

In launching this Karolinska Institutet collaboration with the pharmaceutical company Janssen Pharmaceuticals NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, a number of research posts have been created for observational studies (i.e, real-world evidence). The focus of this cooperation is the follow-up and effects of disease and treatment, using routine data from health care (real-world data) and how they relate to effects in clinical trials, all while social and economic factors will be evaluated. The research will initially focus on method development, depression, prostate cancer, psoriasis, and cancers of the immune-system. The collaboration between Karolinska Institutet and Janssen will be led by Johan Askling, professor at the Department of Medicine in Solna.

source: Karolinska Institute